New Protections in Checklist for Patients, Donors, and Blood

Why It Matters

The tighter verification and stewardship rules improve patient safety, preserve scarce O‑negative blood for high‑risk groups, and reduce costly transfusion errors across the healthcare system.

Key Takeaways

• New checklist mandates repeat or historical ABO/Rh verification for all samples
• Labs must implement processes to conserve group O Rh‑negative red cells
• Mistransfusion risk reduction requires historical record checks for non‑emergent transfusions
• Digital bedside ID systems can satisfy single‑sample credibility for crossmatching
• Accredited labs must enter ABO/Rh data into LIS for traceability

Pulse Analysis

The College of American Pathologists (CAP) has updated its transfusion‑medicine accreditation checklist for 2026, adding a suite of safety controls that affect every hospital blood bank in the United States. The revisions come after a series of high‑profile mismatched transfusion incidents that highlighted gaps in specimen labeling, type verification, and inventory stewardship. By embedding these requirements into the accreditation process, CAP forces laboratories to adopt uniform best practices, turning compliance into a competitive advantage for institutions that prioritize patient safety and operational efficiency.

The most visible change is TRM.40575, which expands ABO and Rh(D) verification to all compatibility‑testing methods. Laboratories must now confirm a patient’s blood type by repeat testing, an alternative sample, or a validated historical record entered by an accredited lab. This eliminates the previous loophole that allowed single‑sample computer crossmatches without independent verification. In parallel, CAP encourages the use of digital bedside identification and other electronic safeguards, ensuring that a single draw can meet credibility standards when paired with robust LIS documentation.

TRM.40707 introduces a stewardship mandate for group O Rh(D)‑negative red blood cells, a scarce resource that historically fuels up to 40 % of non‑O transfusions. By requiring hospitals to track usage and prioritize Rh‑negative patients—especially women of child‑bearing age—the new rule aims to reduce unnecessary exposure and prevent hemolytic disease of the newborn. Combined with the mistransfusion‑risk reduction clause (TRM.30575), which obliges a historical record check for non‑emergent transfusions, the checklist creates a layered safety net that could lower adverse events and improve blood‑bank inventory management across the sector.